ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,441,805, issued on Oct. 14, was assigned to BIOINVENT INTERNATIONAL AB (Lund, Sweden).
"Antagonistic anti-TNFR2 antibodies" was invented by Bjorn Frendeus (Lund, Sweden), Ingrid Teige (Lund, Sweden), Linda Martensson (Bjarred, Sweden), Petra Holmkvist (Kavlinge, Sweden) and Monika Semmrich (Malmo, Sweden).
According to the abstract* released by the U.S. Patent & Trademark Office: "Described are novel antagonistic antibody molecules that specifically bind to TNFR2 on a target cell and thereby block TNF-Alpha binding to TNFR2 and block TNFR2 signaling, wherein the antibody molecules also bind to Fc receptors via the Fc region. Also described is the use of such antibody molecules in tre...